Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in fcγRIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting ADcc activity. In vivo, two B mAb-Ds with 77-81% fucosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig. High fucosylation (>89%) of mouse-human heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat YB2/0 mAb-Ds with <50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. Galactosylation of B mAb-Ds was 57-83% but 15-58% for rodent mAb-Ds. HH mAb-Ds had non-human sugars. These data reveal high galactosylation like anti-D Ig (>60%) together with lower fucosylation (<60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable effective, inexpensive prophylaxis.
which are D-negative with a D-positive fetus or baby. Fetal blood may leak into maternal blood by fetomaternal haemorrhage (FMH) through the placenta, occasionally during pregnancy but more often after parturition 7, 8 with fetal bleeds then usually of greater volume but rarely exceeding 5 mL. FMH is the cause of maternal alloimmunisation 9 . Unique immunologic changes in pregnant and postpartum women induced by placental syncytiotrophoblast microparticles 10, 11 and pregnancy hormones 12 ensure they make strong protective antibody responses to foreign antigens which include, unfortunately, responses to allogeneic blood cells 13 . Prophylactic anti-D accelerates the clearance of fetal D-positive red blood cells (RBC) from the maternal circulation 14 , preventing D-immunisation which may otherwise result in HDFN. Fetal RBC with bound anti-D are removed by the spleen 15 via macrophage IgG Fc receptor (FcγR)IIIa recognition of cell-bound anti-D 16, 17 which triggers phago-cytosis and non-inflammatory intracellular destruction 18 . Consequently, FcγRIIIa-mediated antibody-dependent cellular-cytotoxicity (ADCC) assays are a good predictor of red cell clearance by IgG anti-D 19 .
Anti-D monoclonal antibodies (mAb-Ds) would be safe, inexpensive, standardised products potentially capable of replacing anti-D Ig. Several groups have made mAb-Ds and tested them in relevant biological assays in vitro and in human studies of RBC clearance and prevention of D-immunisation. Surprisingly, mAb-Ds have shown great variability in these studies but none have yet had equivalent activity to anti-D Ig 19 . It was hypothesised that this may be due to differences in their glycosylation 19, 20 , i.e. the composition and linkage of sugars in the oligosaccharide chains attached to the Fc portion of IgG 21 . Human IgG has a highly conserved branched glycan chain covalently attached to Asn297 of each Cγ2 domain (Fig. 1a ). This glycan contains variable amounts of fucose, galactose, sialic acid, and bisecting N-acetylglucosamine (GlcNAc). Remarkably, we have found that alloimmune IgG1 responses against platelets and RBC antigens, including anti-D, are characterised by low fucosylation and increased galactosylation in most sera [22] [23] [24] as well as in the anti-D component of anti-D Ig preparations 25 .
For this study, extensive glycosylation analyses of an anti-D Ig preparation and 23 mAb-Ds produced from cell lines of four species (human, mouse, hamster and rat) were performed independently by two research groups. The mAb-Ds comprised 12 unique clones; 5 of these clones produced anti-D from 2-4 cell lines. Fourteen of these mAb-Ds had been previously tested in 10 clinical studies. Retrospective data analysis of clearance of D-positive RBC by all 14 mAb-Ds and of prevention of D-immunisation by 6 of them is presented here. Glycosylation of IgG1 and IgG3 anti-Ds was determined by high-performance liquid chromatography (HPLC) analysis of fluorescently labelled N-glycans, before and after exoglycosidase digestion. In a second approach, N-glycans from total IgG1 anti-D were analysed by mass spectrometry (MS) after ethyl esterification of sialic acids. In a third approach, MS was also used to analyse IgG1 anti-D Fc-glycopeptides. ADCC assays were performed and glycan structural data were linked to ADCC activity. The data imply that cell line-dependent variations in glycosylation between mAb-Ds had a major influence on biological activity. Functional activity of mAb-Ds in ADCC assays was inversely related to fucosylation. The anti-Ds varied greatly in sensitive natural killer (NK) cell FcγRIIIa-dependent ADCC activity. Four anti-Ds, namely Rhophylac, BRAD5lab-b, Fog1-yb2/0 and G12-yb2/0 exhibited sigmoidal dose-response curves and mediated high potency at relatively low concentrations (<100 ng/ml). All other mAb-Ds tested elicited less activity even at saturating concentrations. At 250 ng/ml, BRAD5lab-b had 66% and 85% greater efficacy than mBRAD5-b and rBRAD5-cho, respectively, while Fog1-yb2/0 and G12-yb2/0 were 95-99% more efficient than their B, NS0 and HH forms in ADCC assays ( Fig. 2a ). Comparison of activity with fucosylation of IgG1 anti-Ds revealed a strong negative correlation with a striking reduction in activity when fucosylation was >80% ( Fig. 2b , top panels). At 25 ng/ml, which is the mean maximum physiological concentration after injection of anti-D Ig 27 , only four anti-Ds (Fog1-yb2/0, G12-yb2/0, BRAD5lab-b as well as Rhophylac) were active ( Fig. 2b , top left panel). At 0.75-2.5 ng/ml (approximate range of detectable anti-D 10 weeks after injection 27 ) only these three mAb-Ds were active ( Fig. 2a ). There was no significant relationship between ADCC activity and sialylation, galactosylation or bisecting GlcNAc of the anti-Ds at either 25 ng/ml or 750 ng/ml ( Fig. 2b , lower panels). However, mBRAD5-b had equal fucosylation as G7-hh (89.5%) but higher ADCC ( Fig. 2a ) and more galactosylation (60% versus 42%) and bisecting GlcNAc (42% versus 2.8%), thus these sugars may have led to enhanced mBRAD5-b interactions with FcγRIIIa. The IgG3 mAb-Ds, mBRAD3-b and rBRAD3-cho, had lower ADCC activity than equivalent forms of BRAD5 ( Fig. 2a ) despite lower fucosylation.
Efficacy of mAb-Ds in human studies was affected by glycosylation.
In autologous studies, clearance of D-positive RBC was more rapid with YB2/0 mAb-Ds (Fog1 28 and R297 29 ) than anti-D Ig, fast with BRAD3clin-b 30 , slower with BRAD3 + BRAD5 (B and CHO) 31 and very slow with Fog1-hh 30 . Clearance by Fog1-hh 30 and Fog1-yb2/0 28 was markedly dissimilar despite identical amino acid sequence, which coincided with much lower fucosylation of Fog1-yb2/0. Unexpectedly, Fog1Δnab-yb2/0 (lacking FcγR interactions 32 ) also cleared RBC 28 . Fucosylation of 1:3 blends of BRAD3 + BRAD5 (B and CHO) was identical (87%) but clearance was slightly greater with mBRAD3-b + mBRAD5-b 31 having increased galactosylation, sialylation and bisection as compared to the CHO-cell produced variants of these antibodies (Table 4 ).
Using D-negative subjects, RBC clearance was slightly less effective with BRAD3clin-b and BRAD5clin-b than anti-D Ig [33] [34] [35] , regardless of the order of injection of anti-D and RBC -anti-D first 33, 34 or RBC first 35 . However, for HH 36, 37 and CHO 38 mAb-Ds injected after RBC, clearance was slow and variable although for two subjects given anti-D (G12-hh) before RBC 37 , clearance was rapid ( Table 5 ).
In the following six months, immune IgG anti-D was detected 4-24 weeks after RBC injection in 0.8% (1 of 119) subjects given B mAb-Ds [33] [34] [35] , 62% receiving HH mAb-Ds 36, 37 , 0% injected with MonoRho-cho 38 and 0% 33,36-38 administered anti-D Ig (Table 5 ). Unexpectedly, IgM anti-D was also detected in 77% of the immunised Table 2 . Analysis of total galactosylation and agalactosyl (G0), monogalactosyl (G1) and digalactosyl (G2) of Fc-glycans from IVIG, Rhophylac anti-D and mAb-Ds. Glycosylation analysis methods used were Flu (NP-HPLC analysis of fluorescently labelled, released N-glycans), Eth (analysis of released N-glycans by MALDI-TOF-MS after ethyl esterification) and GP (analysis of IgG Fc-glycopeptides by LC-MS).
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www.nature.com/scientificreports www.nature.com/scientificreports/ subjects receiving G7-hh and G12-hh 37 . Assessing the efficacy of MonoRho-cho was hindered by "rescue prophylaxis" (anti-D Ig) given to 7 subjects with slow RBC clearance 38 . After protracted studies of BRAD3clin-b and BRAD5clin-b which included two further RBC immunisations at 6 and 9 months, 93% (26 of 28) of the responders who developed anti-D were shown to have been protected from becoming D-immunised to the initial RBC injection by these B mAb-Ds [33] [34] [35] (Table 5 ).
Discussion
Fc N-glycans extend from Asn297 in the N-terminal lower hinge regions of IgG into the Cγ2 inter-domain space, forming weak interactions with the protein [39] [40] [41] . Both the Cγ2 domains and the glycans are to some extent mobile and asymmetric 40, 41 . FcγRIIIa binds to both lower hinge regions 42 . Glycan composition may affect the N-terminal conformation or the relative orientation or mobility of Cγ2 domains, modifying affinity for FcγRs 41 , although the precise mechanisms remain undefined 43 . Glycosylation of Fab (antigen-binding) regions of anti-D is unlikely because the integral membrane RhD proteins are surrounded by negatively charged glycoproteins in the RBC membrane glycocalyx, constricting access to the antigen 44 . In support of this, we recently found a strong selection against the formation of Fab-glycans during hypermutation in anti-D 45 .
Anti-D represents an ideal IgG for structure/function investigation and is unique because mAb-Ds from six types of cell lines could be compared with anti-D Ig synthesised by plasma cells for both in vitro functional activity and in vivo clinical data. The glycosylation of anti-Ds was heterogenous, defined by the producer cells, and influenced their biological and clinical activities.
The contribution of individual sugars to functional activity of IgG is becoming increasingly clear and may prove highly relevant for mAb-Ds.
Fucose (proximal to Asn297) was the first glycan variant found to affect the activity of human IgG1, inhibiting FcγRIIIa-mediated ADCC 46 and phagocytosis 22 . It causes steric inhibition of the Fc-FcγRIIIa interaction 47 . Afucosylated IgG has high affinity for FcγRIIIa 22, 47 displacing plasma IgG and enabling ADCC at low concentrations 48 . Many alloantibodies, but not all, have considerably less fucose than total IgG1 [22] [23] [24] [25] 49 . Fucosylation of anti-D in 11 prophylactic preparations was 56%-91%, while for Rhophylac this was 81% 25 .
The low fucosylation (<35%) of YB2/0 mAb-Ds enabled them to be highly active (effective ADCC and fast red cell clearance) but fucosylation was too high in most of the B, HH and CHO mAb-Ds for high affinity ADCC responses and accelerated red cell clearance. BRAD5lab-b was effective but when produced for clinical use fucosylation was elevated and this came with a lower efficacy. Surprisingly, most B mAb-Ds (including AB5 and JAC10) have minimal ADCC 20,50 perhaps because EBV immortalises immature circulating B cells synthesising highly fucosylated IgG whereas plasma cells secreting low fucosylated protective antibodies lack EBV receptors 51 . The high fucosylation of these B mAb-Ds is likely to explain their low ADCC.
Galactosylation of IgG has been found to be regulated by estrogens 52 , increased during pregnancy 53 and associated with pregnancy-induced remission of rheumatoid arthritis 54 . Agalactosylation levels of IgG have been reported to be two-fold higher in patients with rheumatoid arthritis than controls 55 and associated with www.nature.com/scientificreports www.nature.com/scientificreports/ markers of inflammation 56, 57 . Low galactosylation of anti-proteinase 3 autoantibodies correlated with inflammatory cytokines 58 . In our experiments, galactosylation correlated with moderately increased ADCC of BRAD5lab-b 59 , glycoengineered IgG1 60 and hypo-fucosylated anti-D 61 . Thus, the wide range of galactosylation ranging from Rhophylac and IgG1 B mAb-Ds (60-84% galactosylation with <15% G0) to rodent mAb-Ds (15-57% galactosylation with 18-70% G0) may impact antibody function in various ways. Sialic acid has been described not to alter ADCC activity of IgG1 60 . Similarly, sialylation of anti-D had little or no effect on FcγR binding 61 or macrophage phagocytosis of sensitised RBC 62 . Low sialylation of CHO and YB2/0 mAb-Ds (mean 8%) and lack of the α2,6-linkage on CHO mAb-Ds may make them liable to inflammatory responses. In addition, non-human Neu5Gc on NS0, HH and G12-yb2/0 mAb-Ds may be immunogenic 63, 64 .
The biological relevance of bisecting GlcNAc is uncertain. Increasing it has been reported to enhance FcγRIIIa-mediated ADCC, possibly by affecting fucosylation 65, 66 , but recently, little effect has been found for monoclonal anti-D 61 . Bisection was very high on most B mAb-Ds.
Alpha-galactose (α-Gal epitope: Galα1-3Galβ1-(3)4GlcNAc-R) is synthesised by all mammals except humans, apes and Old World monkeys, which produce anti-Gal 67 , comprising ~1% of human IgG 68 . Humans also have high concentrations of anti-Neu5Gc (usually higher than anti-B (blood group antibody)) 64 . These natural www.nature.com/scientificreports www.nature.com/scientificreports/ antibodies may bind mAbs expressing xenogeneic α-Gal and Neu5Gc epitopes, forming immune complexes and increasing uptake of target cells to antigen-presenting cells and immunogenicity. All NS0 and HH mAb-Ds expressed α-Gal, as reported previously 69 , and Neu5Gc, also found on mAbs from some murine myelomas 70 . These xenogeneic epitopes may have caused HH mAb-Ds to stimulate anti-D responses, not prevent them. The findings by one laboratory of low amounts of α-Gal on some human B mAb-Ds cultured in the absence of animal material are unexpected and should be taken with caution as further studies would be needed to substantiate this.
IgG3 anti-D comprises 10% of the anti-D in prophylactic preparations on average 71 but is relatively inefficient in ADCC compared to IgG1 anti-D as is BRAD3 (IgG3) compared to BRAD5 (IgG1) 72 . ADCC assays measured FcγRIIIa-mediated haemolysis by NK cells although in vivo FcγRIIIa-bearing splenic macrophages phago-cytose anti-D opsonised RBC 16, 17 . In vivo, BRAD3clin-b efficiently cleared RBC 30, 33 . In vitro, RBC opsonised with BRAD3lab-b had greater mean binding to splenic macrophages in cryostat sections than BRAD5lab-b opsonised RBC (58.6 and 25.8 respectively) 73 . Additionally, using monocyte-derived macrophages, IgG3 mAb-Ds mediated higher ADCC than IgG1 mAb-Ds (96% versus 26%) 50 . This difference in activity may be explained because glycoforms of FcγRIIIa vary between NK cells and monocytes 74 which may affect affinity to IgG subclasses and binding of differentially glycosylated IgG. Recognition of afucosylated IgG by FcγRIIIa is in part mediated through carbohydrate-carbohydrate interactions involving the N162-glycan found on this receptor 47 .
The role of cells and FcγRs in RBC clearance is becoming clearer. In vitro, phagocytosis of anti-D opsonised RBC by monocytes is mediated by FcγRI, with the extent of phagocytosis proportional to anti-D coverage on RBCs 50 . FcγRI is also present on splenic red pulp macrophages and although at low expression compared to FcγRIIIa, it gives a major contribution to phagocytosis 75 . This may be due to upregulation of surface expression of FcγRI after stimulation of FcγRIIIa by binding opsonised RBC or by inflammation 75 . Thus in vivo, it is likely that opsonised RBC are selected and captured by splenic macrophages through FcγRIIIa binding afucosylated anti-D followed by FcγRI-mediated internalisation. The spleen has the capacity to phagocytose all the fetal RBC in the majority of FMH (volumes over 20 ml fetal RBC are exceptional) without producing spherocytes or free haemoglobin. RBC with the highest opsonisation will be removed first, the rate of clearance correlating with the amount of RBC-bound anti-D 14 (and indirectly to D antigen levels), resulting in progressive slowing of clearance of RBC with decreasing anti-D opsonisation. Notably, antigen masking may only occur to a minor extent, as doses of anti-D cover only about 8%-20% of D antigen sites on RBC 76 .
Although the mechanism of anti-D prophylaxis has not been fully elucidated, clinical observations and studies performed after the introduction of anti-D Ig suggest it elicits some immunomodulatory processes. (a) Prophylactic anti-D appears to have long-term effects. HDFN was found less severe in subsequent pregnancies of women who had failures of postnatal prophylaxis compared to infants of multiparae women who had no pro-phylaxis 77 . Antenatal prophylaxis given only during first pregnancies, together with postnatal prophylaxis,
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Comments on clearance Table 5 . Clearance of allogeneic D-positive RBC in D-negative subjects by anti-D and subsequent protection against D-immunization (prophylaxis).
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resulted in a 12-fold reduction in cases with D-immunisation in the second pregnancies 78 . These findings were recently confirmed 79 . It was suggested that the D-immune responses could have been modified by giving anti-D after the responses had started but before they had matured 77, 78 . (b) Women with large fetal bleeds (FMH over 20 ml) who were given appropriate doses of anti-D Ig but had persistence of some circulating fetal RBC 6 days after delivery were subsequently found to be protected from D-immunisation, indicating that the immune response had been prevented by the sequestered RBC 80 . (c) IgG anti-Kell (K) injected into K-D-subjects after immunisation with K+ D+ RBC gave a 10-fold reduction in anti-D responders, compared to a control group not given anti-K. This demonstrated that after rapid clearance of RBC to the spleen, antibody-mediated immune suppression is not antigen specific but cell-specific, inhibiting antibody formation to all antigens on the RBC 81 .
(d) Besides destruction of the RBC by anti-D Ig, another potential mechanism may be suppression of primed antigen-specific B cells by co-cross-linking B cell receptors (binding RBC antigens) and inhibitory FcγRIIb (with anti-D Ig) (reviewed in 76 ). Of note, it was reported that the YB2/0 form of a mAb-D, T125, had greater interactions with both FcγRIIIa and FcγRIIb than the CHO form, thus indicating that low fucosylated anti-D would be effective in this mechanism of B cell suppression 82 as well as in rapid RBC clearance 29 . (e) Other "non-specific" immunomodulatory effects of prophylactic anti-D could be caused by the anti-D or many other alloantibodies in the donor pool of immuno-globulins (similar to IVIG) using these mechanisms, such as reductions of anti-Fy a in a case report 83 and of anti-HLA sensitisation in a large survey 84 . HLA class I antigens (Bg) are expressed on most cells including RBC of some normal donors 85 . (f) Animal models, unfortunately, are generally unsatisfactory for understanding anti-D prophylaxis; experiments in immunocompetent mice using xenogeneic cells or glycoproteins elicit innate and/or inflammatory reactions, quite unlike allogeneic RBC and anti-D Ig in humans 76 . Inflammatory responses must be avoided for RhD prophylaxis. If inflammation accompanies RBC destruction, splenic macrophages mature to DCs, present antigen to T helper (Th) cells and initiate antibody responses to allogeneic proteins 18 . Understandably, it must not occur with mAb-Ds or immune anti-D may be produced.
Several factors may cause inflammation. (a) Pregnant women have strong systemic immunity with mild inflammation 10, 11 and skewing towards antibody (Th2) responses 86 whilst maintaining local (uterine) tolerance to the fetus 13 . They make robust alloantibody responses to small volumes of allogeneic blood. Consequently, most protein blood groups on RBC and alloantigens on platelets were discovered by investigating cases of HDFN and fetal and neonatal alloimmune thrombocytopenia (FNAIT). (b) Recognition of cells by innate immune receptors may induce phagocytosis accompanied by inflammatory cytokines, promoting antigen presentation; this was observed experimentally for RBC immunisation 87 . (c) Extracellular haemolysis liberates haemoglobin, its breakdown products induce systemic inflammatory responses (febrile reactions and cytokine storms) which can be dangerous. Haemolysis underlies the pathology of HDFN, delayed haemolytic transfusion reactions, and rare reactions of patients with idiopathic thrombocytopenia treated with anti-D 88 , all occurring when the phagocytic capacity of splenic macrophages is saturated and RBC are haemolyzed extracellularly.
Anti-D prophylaxis may be mediated or influenced by cytokines but data are limited. Interleukin (IL)-1Ra, an anti-inflammatory cytokine, was detected during monocyte phagocytosis of BRAD3lab-b-opsonised RBC in vitro 89 . Modest increases of tumour necrosis factor-α but not interferon-γ (both pro-inflammatory) were observed briefly (at 4 h) after infusion of RBC coated with Rhophylac 300 or R297-yb2/0 29 . After antenatal pro-phylaxis, slight reductions of IL-1Ra (pro-inflammatory effect) were observed in plasma of 7 of 10 women while modest increases of transforming growth factor-β1 and prostaglandin E2 (immunoregulatory) were recorded in 7 and 5 of these women, respectively 90 . However, no tests to detect fetal cells (FMH) were performed so it is possible these changes in 3 of the 17 cytokines tested 90 were due to the immunoglobulin component, known to have immunomodulatory effects.
Great care must be taken to ensure the safety and efficacy of mAb-Ds at preventing D-immunisation before trials are performed in pregnant (and postpartum) women. First, anti-D responses are slow and low titre; half of the women immunised during pregnancy produce serologically detectable anti-D by six months post-partum and half of them in subsequent pregnancies, presumably after FMH 91 . Gunson et al. proposed this involves slow protracted phagocytosis of fetal RBC as they become effete 92 . Second, normal adults do not have the enhanced humoral immunity of pregnant women; anti-D developed in 50% of subjects only after 2-5 injections of D-positive RBC and rapid clearance of these RBC often occurred before anti-D was detected serologically 93 . Therefore, in the early clinical trials of anti-D, subjects were re-immunised with D-positive RBC several times between 6 and 12 months [33] [34] [35] 94 . Primary and secondary anti-D responses were detectable 2-4 months or 1-4 weeks after re-immunisation, respectively. This determines which subjects were (a) D-immunised by the first injection of RBC (failure of prophylaxis), (b) D-immunised after RBC challenge (protection by prophylaxis) and (c) non-responders who never make anti-D (non-informative).
Thus both appropriate clinical testing and anti-D glycosylation are required for success with prophylactic mAb-Ds. The previously published clinical trial data of the anti-Ds in this study can be summarised. Anti-D Ig: high ADCC, very rapid RBC clearance, prevented D-immunisation. B mAb-Ds: (BRAD3, BRAD5) medium ADCC, fast clearance, prevented D-immunisation in 93% subjects, insufficient dose. HH mAb-Ds: (Fog1, AD1, G7, G12) low ADCC, variable and slow clearance, stimulated D-immunisation. CHO mAb-Ds: (BRAD3, BRAD5, MonoRho) low ADCC, slow and variable clearance, MonoRho may have prevented D-immunisation but this is not proven. YB2/0 mAb-Ds: (Fog1, Fog1Δnab, R297) very high ADCC, extremely rapid clearance.
Unfortunately, after much work over three decades, none of the mAb-Ds in this study and also Sym001-cho (Rozrolimupab) 95 are still in clinical development for prophylaxis against HDFN although the results of prevention of D-immunisation in a phase II/III trial of Roledumab-yb2/0 (R297 with low fucosyl transferase) 96, 97 are awaited with great interest.
Prophylaxis against FNAIT has been proposed and anti-HPA-1a immunoglobulin is being prepared from women immunised by pregnancy for trials 98 . Because anti-HPA-1a is rarely produced after Glycosylation analysis 2: N-glycan analysis at Leiden University Medical Center. IgG Total N-glycosylation analysis (Eth). After protein denaturation, N-glycans were released with 1 mU recombinant peptide-N-glycosidase F (PNGase F; Roche Diagnostics, Mannheim, Germany) at 37 °C overnight as described previously 104, 105 . The selective ethyl-esterification of 2,6-linked sialic acids and lactonization of 2,3-linked sialic acid was performed on the released N-glycans 106 , followed by glycan purification by HILIC-SPE using cotton as stationary phase 107 www.nature.com/scientificreports www.nature.com/scientificreports/ was performed on mostly sialylated variants of IgG glycans via laser-induced dissociation, and compositions as well as structural features of N-glycans were confirmed on the basis of the observed fragment ions (not shown).
Spectra were exported as text and subjected to recalibration and data extraction using an in-house developed Python script. Glycan peaks were detected and extracted using a signal/noise cut-off of 3. Total glycan intensity per spectrum was normalised to 100%, and derived traits were calculated based on the compositional features ( Supplementary Tables S3 and S4 ) (hexose = H; N-acetylhexosamine = N; fucose = F; α2,6-linked N-acetylneuraminic acid = E; α2,3-linked N-acetylneuraminic acid = L; α2,6-linked N-glycolylneuraminic acid = Ge; α2,3-linked N-glycolylneuraminic acid = Gl). Fc glycopeptide analysis (N-glycosylation) at Leiden University Medical Center (GP). IgG was enzymatically digested with trypsin and analysed by reverse phase-nanoLC-MS. Electrospray ionisation was achieved with a CaptiveSpray nanoBooster (Bruker Daltonics) using acetonitrile-enriched nitrogen gas to enhance sensitivity. Glycopeptides were detected using a quadrupole-time-of-flight (TOF) mass spectrometer (MS) (maXis impact HD ultra-high resolution QTOF; Bruker Daltonics) 108 . Double and triple charged tryptic Fc glycopeptide signals were integrated and normalised to the subclass-specific total glycopeptide intensity. Quality of mass spectra was evaluated based on intensities of total IgG1 glycoforms. Glycosylation traits were calculated as detailed in Supplementary Table S3 .
Glycosylation analysis 3: IgG

Analysis of mAb-D glycosylation in small scale earlier studies.
Methods used for other studies reported in Supplementary Table S1 were MALDI-TOF-MS analysis of IgG1 Fc-glycopeptides 25 , analysis by HVE-AEC, gel filtration chromatography and Concanavalin A binding of oligosaccharides released by hydrazinolysis 109 , quantitation of % G0 by binding of GlcNAc-specific mAb GN7 59 , chromatographic separation of fluorescently labelled neutral oligosaccharides 49 , enzymatically released glycans analysed by HPCE-LIF 82 and FAB-MS and MALDI-MS of permethylated N-glycans (Carbohydrate structure of rBRAD-3 and rBRAD-5; Joan Dalton, BioProducts Laboratory, UK, email, September 26, 2007; permission to publish subsequently given).
ADcc assay. Peripheral blood mononuclear cells (PBMC) depleted of adherent monocytes were incubated in triplicate for 16 h at 37 °C with papainized 51 Cr-labelled group OR 1 R 2 RBC (15:1 ratio) and anti-D in RPMI1640 containing 3% AB serum (to block FcγRI on residual monocytes) 50 and 7% fetal calf serum; after centrifugation, radioactivity was determined in aliquots of supernatant 72 . The percent specific lysis (% haemo-lysis) was calculated as: % specific lysis = 100 × (experimental release -spontaneous release)/(maximum release -spontaneous release). To confirm FcγR utilisation, lysis by IgG1 anti-D was blocked by anti-FcγRIII (3G8) but not by anti-FcγRII (IV.3) 50 .
Analysis of data from previous clinical trials of RBC clearance and prevention of D-immunization.
The efficacy of prophylactic anti-D Ig depends on removal of fetal RBC from the circulation by 72 hours 110 . Clinically, tests for FMH are performed to determine whether fetal D-positive RBC have been cleared by this time 111 . For initial clinical trials, pre-menopausal women are not enrolled because they might become D-immunised which could lead to HDFN in subsequent pregnancies. Early studies showed that if anti-D prevented D-immunisation in men, it would be suitable for prophylaxis in women. Using healthy male volunteers, eight mAb-Ds had been tested in four autologous RBC clearance studies and seven mAb-Ds in five allogeneic RBC clearance studies. All the trial protocols varied; details of methods, ethics approval and informed consent are given in the original papers cited in Tables 4 and 5 . Autologous RBC clearance measured the extent of radioactivity remaining in blood of D-positive subjects after injection of their ex vivo 51 Cr labelled RBC coated with anti-D. Study periods were between 1 h and 6 days after injection. Allogeneic studies measured clearance of D-positive RBC (labelled with 51 Cr or detected by flow cytometry) injected into D-negative recipients before (simulating postnatal prophylaxis) or after (equivalent to antenatal prophylaxis) anti-D administration, with blood samples taken up to 7 days. To assess whether mAb-D could prevent D-immunisation, these subjects were then tested regularly (every 2 or 4 weeks) for 6 months to detect anti-D responses (indicating failure of prophylaxis). In studies of B mAb-Ds, subjects were then re-immunised with D-positive RBC at 6 and 9 months and tested regularly up to a year to determine which were responders to these unprotected immunisations who had been prevented from making anti-D after the first RBC injection by mAb-Ds.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary Information files. Not all mAb-Ds (antibodies or cell lines) may be available due to being produced many years ago in laboratories that have since ceased working on them or closed down.
